The US Food and Drug Administration has rejected Eiger BioPharmaceuticals’ request to meet with the agency regarding peginterferon lambda, its repurposed hepatitis D treatment for use in COVID-19. The company asked for the meeting to discuss an emergency use authorization in September based on data […]
Pharma Plays Balancing Act with US Democrats After Drug Pricing Reform Passes
While pharma mulls over how to fight back over the new US drug pricing reforms, they are carefully weighing how to navigate negotiations with Democrats. Lawsuits have already been filed, but the timeline for those is yet to be determined, so the industry can’t be too hardball with the party if it […]
Amylyx Takes Heat for $158,000 Annual Price of New ALS Drug
Amylyx Pharmaceuticals’ new amyotrophic lateral sclerosis (ALS) drug was approved by the US Food and Drug Administration last week and is already taking flak. The company has set the annual price of the drug to $158,000, a number decried by many as exorbitant. According to ICER, the drug should be […]
Natalie Douglas and Patti Peeples Join Global Pricing Innovations Board of Directors
Global Pricing Innovations (GPI) has announced that Natalie Douglas and Patti Peeples, PhD, will join the company’s board of directors. Douglas, who will join as the new Chair, is the founder of RealiTi Health and a longtime investor and entrepreneur in the medical and biotech industries. Peeples is […]
FTC Chair Plans to Explore All Options in PBM Investigations
The chair of the US Federal Trade Commission (FTC), Lina Khan, has pledged to use all the tools at her disposal to investigate the practices of pharmacy benefit managers (PBMs), which have recently faced increasing scrutiny. This is due to allegations of anti-competition and price fixing. A formal […]
US State of Georgia Reaches $3.3 Million Settlement with Teva in Price Fixing Lawsuit
Teva Pharmaceuticals has settled yet another lawsuit with the government of a US State, this time with Georgia. The company reached a settlement worth $3.3 million with the state, the third and most expensive settlement of its kind. The lawsuits faced by the company surrounded claims of price […]
Generics Companies Considering Cuts in Europe Over Drug Pricing Laws and Energy Crisis
World events and pricing legislation are putting pressure on generic manufacturers, according to an open letter written by the lobbying group Medicines for Europe. The industry group notes that raw material costs have skyrocketed by between 50%-160%, dwarfing the inflation rate of 9%. Energy costs […]
Jennifer Fillman Takes Role at Genesis Research
The former senior vice president and CFO of Clinical Solutions at Syneos Health has taken on a new position as CFO for Genesis Research. Jennifer Fillman will take over the position at Genesis, a health economics and outcomes research (HEOR) company known for its real-world evidence (RWE)-based […]
Novartis Leans into US Market, Drug Pricing Reform Notwithstanding
Novartis investors were told that the pharma giant would laser focus on the US market in an event on Thursday, September 22nd. The announcement comes weeks after the US government passed drug pricing reform which critics argued would stifle innovation and investments in the nation. This push would […]
BioGene Scores NICE Approval for Rare Lymphoma Drug Brukinsa
The UK’s National Institute for Health and Care Excellence (NICE) has approved BioGene’s drug Brukinsa for patients with Waldenstrom macroglobulinemia (WM), a rare form of B-cell lymphoma. The drug, approved for the same purpose last year in the US, will meet a previously unmet need due to issues […]
